GSA Capital Partners’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-19,597
| Closed | -$249K | – | 2050 |
|
|
2024
Q3 | $249K | Buy |
+19,597
| New | +$249K | 0.02% | 1320 |
|
|
2024
Q2 | – | Sell |
-14,937
| Closed | -$224K | – | 2043 |
|
|
2024
Q1 | $224K | Buy |
+14,937
| New | +$224K | 0.02% | 1358 |
|
|
2023
Q4 | – | Sell |
-10,189
| Closed | -$143K | – | 1956 |
|
|
2023
Q3 | $143K | Buy |
+10,189
| New | +$143K | 0.01% | 1349 |
|
|
2023
Q1 | – | Sell |
-31,046
| Closed | -$275K | – | 1953 |
|
|
2022
Q4 | $275K | Sell |
31,046
-18,176
| -37% | -$161K | 0.03% | 993 |
|
|
2022
Q3 | $410K | Buy |
49,222
+951
| +2% | +$7.92K | 0.05% | 723 |
|
|
2022
Q2 | $395K | Sell |
48,271
-8,953
| -16% | -$73.3K | 0.06% | 650 |
|
|
2022
Q1 | $498K | Buy |
57,224
+18,160
| +46% | +$158K | 0.07% | 536 |
|
|
2021
Q4 | $371K | Buy |
39,064
+18,559
| +91% | +$176K | 0.05% | 794 |
|
|
2021
Q3 | $345K | Sell |
20,505
-7,378
| -26% | -$124K | 0.04% | 921 |
|
|
2021
Q2 | $426K | Buy |
27,883
+4,339
| +18% | +$66.3K | 0.05% | 734 |
|
|
2021
Q1 | $459K | Buy |
+23,544
| New | +$459K | 0.08% | 401 |
|
|
2018
Q1 | – | Sell |
-10,200
| Closed | -$380K | – | 1840 |
|
|
2017
Q4 | $380K | Buy |
10,200
+900
| +10% | +$33.5K | 0.02% | 1090 |
|
|
2017
Q3 | $293K | Buy |
+9,300
| New | +$293K | 0.02% | 1265 |
|